Insmed Incorporated (INSM) Reports Q1 2026 Results

Insmed Incorporated (NASDAQ:INSM) is one of the 8 Most Promising Biotech Stocks to Buy Now.

On May 7, Insmed Incorporated (NASDAQ:INSM) reported first-quarter 2026 financials. The company posted a total revenue of $306.0 million because of BRINSUPRI generating $207.9 million and ARIKAYCE contributing $98.1 million. BRINSUPRI revenue surged 44% sequentially from Q4 2025, while ARIKAYCE rose 6% YoY, showing international expansion.

Will Lewis, CEO, said in the release that commercial momentum and pipeline progress continued to build, spotlighting BRINSUPRI’s launch path and ENCORE data strength. Insmed Incorporated (NASDAQ:INSM) also stated that the study fulfilled its primary and all multiplicity-controlled secondary goals. It prepared ARIKAYCE for an SNDAs filing with the FDA in the second half of 2026.

Guidance remained solid. The company reiterated its forecasts for BRINSUPRI revenue of at least $1 billion in 2026 and ARIKAYCE sales of $450 million to $470 million. It also launched the Phase 3 PALM-PAH study of TPIP in April, adding to its late-stage pipeline.

Insmed Incorporated (INSM) Reports Q1 2026 Results

Pixabay/Public Domain

Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical company that produces and markets medicines for rare diseases. It focuses on the Brensocatib and Treprostinil Palmitil Inhalation Powder pipelines.

While we acknowledge the risk and potential of INSM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than INSM and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.